Evotec (EVO) said Thursday it expects 2025 revenue of 840 million euros to 880 million euros ($953.9 million to $999.3 million).
Four analysts polled by FactSet expect 851.4 million euros.
The AI-powered medical data collation firm said it expects a 2024 to 2028 compound annual growth rate of 8% to 12%.
Furthermore, the company said tariffs and potential US government funding cuts are expected to have a "limited impact" on its business. It is also planning to simplify its business model and reduce its asset portfolio by around 30%.
Additionally, Evotec plans to use automation and cost-lowering initiatives to produce around 50 million euros in gross savings by 2028 on top of a priority reset that is expected to deliver 40 million euros a year in savings.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。